Neuregulins

Handbook of Biologically Active Peptides

Volumn , Issue , 2013, Pages 1633-1638

  Seroogy, Kim B ^a   Dickerson, Jonathan W ^b   Cassella, Sarah N ^a   Zhang Auberson, Lixin ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884916855     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-385095-9.00223-2     Document Type: Chapter

References (35)

1. Birchmeier C. ErbB receptors and the development of the nervous system. Exp Cell Res 2009, 315:611-618.
2. Buonanno A. The neuregulin signaling pathway and schizophrenia: from genes to synapses and neural circuits. Brain Res Bull 2010, 83:122-131.
3. Buonanno A., Fischbach G.D. Neuregulin and ErbB receptor signaling pathways in the nervous system. Curr Opin Neurobiol 2001, 11:287-296.
4. Cannella B., Hoban C.J., Gao Y., Garcia-Arenas R., Lawson D., Marchionni M., et al. The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model of multiple sclerosis. Proc Natl Acad Sci U S A 1998, 95:10100-10105.
5. 1 protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem 2011, 117:1066-1074.
6. Carpenter G. ErbB-4: mechanism of action and biology. Exp Cell Res 2003, 284:66-77.
7. Chaudhury A.R., Gerecke K.M., Wyss J.M., Morgan D.G., Gordon M.N., Carroll S.L. Neuregulin-1 and erbB4 immunoreactivity is associated with neuritic plaques in Alzheimer disease brain and in a transgenic model of Alzheimer disease. J Neuropathol Exp Neurol 2003, 62:42-54.
8. Citri A., Skaria K.B., Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003, 284:54-65.
9. Dickerson J.W., Hemmerle A.M., Numan S., Lundgren K.H., Seroogy K.B. Decreased expression of ErbB4 and tyrosine hydroxylase mRNA and protein in the ventral midbrain of aged rats. Neuroscience 2009, 163:482-489.
10. Dimayuga F.O., Ding Q., Keller J.N., Marchionni M.A., Seroogy K.B., Bruce-Keller A.J. The neuregulin GGF2 attenuates free radical release from activated microglial cells. J Neuroimmunol 2003, 136:67-74.
11. Eilam R., Pinkas-Kramarski R., Ratzkin B.J., Segal M., Yarden Y. Activity-dependent regulation of Neu differentiation factor/neuregulin expression in rat brain. Proc Natl Acad Sci U S A 1998, 95:1888-1893.
12. Esper R.M., Pankonin M.S., Loeb J.A. Neuregulins: versatile growth and differentiation factors in nervous system development and human disease. Brain Res Rev 2006, 51:161-175.
13. Falls D.L. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 2003, 284:14-30.
14. Iaci J.F., Ganguly A., Finklestein S.P., Parry T.J., Ren J., Saha S., et al. Glial growth factor 2 promotes functional recovery with treatment initiated up to 7 days after permanent focal ischemic stroke. Neuropharmacology 2010, 59:640-649.
15. Jabbour A., Hayward C.S., Keough A.M., Koltyar E., McCrohon J.A., England J.F., et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favorable acute and chronic haemodynamic responses. Eur J Heart Fail 2011, 13:83-92.
16. Kastin A.J., Akerstrom V., Pan W. Neuregulin-1-beta1 enters brain and spinal cord by receptor-mediated transport. J Neurochem 2004, 88:965-970.
17. Longart M., Liu Y., Karavanova I., Buonanno A. Neuregulin-2 is developmentally regulated and targeted to dendrites of central neurons. J Comp Neurol 2004, 472:156-172.
18. Mei L., Xiong W- C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nature Rev Neurosci 2008, 9:437-452.
19. Rico B., Marin O. Neuregulin signaling, cortical circuitry development and schizophrenia. Curr Opin Genet Dev 2011, 21:262-270.
20. Rösler T.W., Depboylu C., Arias-Carrión O., Wozny W., Carlsson C., Höllerhage M., et al. Biodistribution and brain permeability of the extracellular domain of neuregulin-1β1. Neuropharmacol 2011, 61:1413-1418.
21. Silberberg G., Darvasi A., Pinkas-Kramarski R., Navon R. The involvement of ErbB4 with schizophrenia: association and expression studies. Am J Med Genet B Neuropsychiatr Genet 2006, 141B:142-148.
22. Sithanandam G., Anderson L.M. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Therapy 2008, 15:413-448.
23. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002, 71:877-892.
24. Talmage D.A., Role L.W. Multiple personalities of neuregulin gene family members. J Comp Neurol 2004, 472:134-139.
25. Ting A.K., Chen Y., Wen L., Yin D.-M., Shen C., Tao Y., et al. Neuregulin 1 promotes excitatory synapse development and function in GABAergic interneurons. J Neurosci 2011, 31:15-25.
26. Tzahar E., Waterman H., Chen X., Levkowitz G., Karunagaran D., Lavi S., et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996, 16:5276-5287.
27. Viehover A., Miller R.H., Park S.K., Fischbach G., Vartanian T. Neuregulin: an oligodendrocyte growth factor absent in active multiple sclerosis lesions. Dev Neurosci 2001, 23:377-386.
28. Veikkolainen V., Vaparanta K., Halkilahti K., Iljin K., Sundvall M., Elenius K. Function of ERBB4 is determined by alternative splicing. Cell Cycle 2011, 10:2647-2657.
29. Wang Y.C., Chen J.Y., Chen M.L., Chen C.H., Lai I.C., Chen T.T., et al. Neuregulin 3 genetic variations and susceptibility to schizophrenia in a Chinese population. Biol Psychiatry 2008, 64:1093-1096.
30. Woo R.S., Lee J.H., Yu H.N., Song D.Y., Baik T.K. Expression of ErbB4 in the neurons of Alzheimer's disease brain and APP/PS1 mice, a model of Alzheimer's disease. Anat Cell Biol 2011, 44:116-127.
31. Xu Z., Croslan D.R., Harris A.E., Ford G.D., Ford B.D. Extended therapeutic window and functional recovery after intraarterial administration of neuregulin-1 after focal ischemic stroke. J Cereb Blood Flow Metab 2006, 26:527-535.
32. Yurek D.M., Zhang L., Fletcher-Turner A., Seroogy K.B. Supranigral injection of neuregulin1β induces striatal dopamine overflow. Brain Res 2004, 1028:116-119.
33. Yurek D.M., Seroogy K.B. Neurotrophic factor protection of dopaminergic neurons. Neurobiology of the neurotrophins 2001, 355-397. Sulburger & Graham Publishing, New York. I. Mochetti (Ed.).
34. Zhang L., Fletcher-Turner A., Lundgren K.H., Marchionni M., Yurek D.M., Seroogy K.B. Neurotrophic and neuroprotective effects of the neuregulin glial growth factor-2 on dopaminergic neurons in rat primary midbrain cultures. J Neurochem 2004, 91:1358-1368.
35. Zheng Y., Watakabe A., Takada M., Kakita A., Namba H., Takahashi H., et al. Expression of ErbB4 in substantia nigra dopamine neurons of monkeys and humans. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:701-706.